These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2858256)

  • 1. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
    Marshall PE; Landis DM
    Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
    Marshall PE; Landis DM; Zalneraitis EL
    Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia.
    Albin RL; Reiner A; Anderson KD; Penney JB; Young AB
    Ann Neurol; 1990 Apr; 27(4):357-65. PubMed ID: 1972318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of somatostatin immunoreactivity in the forebrain of the squirrel monkey: basal ganglia and amygdala.
    Desjardins C; Parent A
    Neuroscience; 1992; 47(1):115-33. PubMed ID: 1349731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease.
    Rossor MN; Hunt SP; Iversen LL; Bannister R; Hawthorn J; Ang VT; Jenkins JS
    Brain Res; 1982 Dec; 253(1-2):341-3. PubMed ID: 6217862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease.
    Morton AJ; Nicholson LF; Faull RL
    Neuroscience; 1993 Mar; 53(1):159-68. PubMed ID: 7682296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The distribution of substance P in the primate basal ganglia: an immunohistochemical study of baboon and human brain.
    Beach TG; McGeer EG
    Neuroscience; 1984 Sep; 13(1):29-52. PubMed ID: 6208509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
    Glass M; Faull RL; Dragunow M
    Neuroscience; 1993 Oct; 56(3):523-7. PubMed ID: 8255419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.
    Richfield EK; Herkenham M
    Ann Neurol; 1994 Oct; 36(4):577-84. PubMed ID: 7944290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acidic and basic fibroblast growth factor-like immunoreactivity in the striatum and midbrain in Huntington's disease.
    Tooyama I; Kremer HP; Hayden MR; Kimura H; McGeer EG; McGeer PL
    Brain Res; 1993 Apr; 610(1):1-7. PubMed ID: 7686078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.
    Norris PJ; Waldvogel HJ; Faull RL; Love DR; Emson PC
    Neuroscience; 1996 Jun; 72(4):1037-47. PubMed ID: 8735228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance P and substance P receptor histochemistry in human neurodegenerative diseases.
    Kowall NW; Quigley BJ; Krause JE; Lu F; Kosofsky BE; Ferrante RJ
    Regul Pept; 1993 Jul; 46(1-2):174-85. PubMed ID: 7692486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
    Perry TL; Hansen S; Kloster M
    N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
    Dawbarn D; De Quidt ME; Emson PC
    Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some remarks concerning the possible role of brain monoamines (dopamine, noradrenaline, serotonin) in mental disorders.
    Hornykiewicz O
    J Psychiatr Res; 1974; 11():249-53. PubMed ID: 4282386
    [No Abstract]   [Full Text] [Related]  

  • 18. Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease.
    Kiyama H; Seto-Ohshima A; Emson PC
    Brain Res; 1990 Aug; 525(2):209-14. PubMed ID: 2147568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease.
    Sun Z; Del Mar N; Meade C; Goldowitz D; Reiner A
    Neurobiol Dis; 2002 Dec; 11(3):369-85. PubMed ID: 12586547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.